The STARNET study found that cardiometabolic disease risk loci share cis- and trans-gene regulation.
At the American Association for Clinical Chemistry meeting, Theranos CEO Elizabeth Holmes said her company is working on third-party review and publications of the firm's technologies and tests.
A study in NEJM found that rare, loss-of-function mutations in the asialoglycoprotein receptor gene coincide with lower non-HDL levels and decreased coronary artery disease risk.
DeCode Genetics' Kari Stefansson and his colleagues uncovered a dozen genetic variants that influence blood lipids, and explored links to coronary artery disease.
The researchers found that older people with clear arteries had noticeably higher levels of CXCL5 compared with older people with more plaque buildup.
Independent research groups garnered evidence that mutations to the ANGPTL4 gene can lower blood triglyceride levels and reduce coronary artery disease risk.
Researchers found that reporting an incidental genetic finding doesn't cause patients extra anxiety and may lead to positive changes if the disease is actionable.
The deal with Quest enables clinicians to order blood draws on patients through its facilities for testing with CardioDx's Corus CAD test.
In Nature this week: DNA methylation loss in certain oil palm trees, coronary artery disease meta-analysis, and more.
An international research consortium finds a genetic link between height and risk of coronary artery disease.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.